Literature DB >> 9603117

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

T A Seemungal1, G C Donaldson, E A Paul, J C Bestall, D J Jeffries, J A Wedzicha.   

Abstract

Exacerbations occur commonly in patients with moderate or severe chronic obstructive pulmonary disease (COPD) but factors affecting their severity and frequency or effects on quality of life are unknown. We measured daily peak expiratory flow rate (PEFR) and daily respiratory symptoms for 1 yr in 70 COPD patients (52 male, 18 female, mean age [+/- SD] 67.5 +/- 8.3 yr, FEV1 1.06 +/- 0.45 L, FVC 2.48 +/- 0.82 L, FEV1/FVC 44 +/- 15%, FEV1 reversibility 6.7 +/- 9.1%, PaO2 8.8 +/- 1.1 kPa). Quality of life was measured by the St. George's Respiratory Questionnaire (SGRQ). Exacerbations (E) were assessed at acute visit (reported exacerbation) or from diary card data each month (unreported exacerbation). In 61 (87%) patients there were 190 exacerbations (median 3; range, 1 to 8) of which 93 (51%) were reported. There were no differences in major symptoms (increase in dyspnea, sputum volume, or purulence) or physiological parameters between reported and unreported exacerbations. At exacerbation, median peak flow fell by an average of 6.6 L/min (p = 0.0003). Using the median number of exacerbations as the cutoff point, patients were classified as infrequent exacerbators (E = 0 to 2) or frequent exacerbators (E = 3 to 8). The SGRQ Total and component scores were significantly worse in the group that had frequent exacerbations: SGRQ Total score (mean difference = 14.8, p < 0.001), Symptoms (23.1, p < 0.001), Activities (12.2, p = 0.003), Impacts (13.9, p = 0.002). However there was no difference between frequent and infrequent exacerbators in the fall in peak flow at exacerbation. Factors predictive of frequent exacerbations were daily cough (p = 0.018), daily wheeze (p = 0.011), and daily cough and sputum (p = 0.009) and frequent exacerbations in the previous year (p = 0.001). These findings suggest that patient quality of life is related to COPD exacerbation frequency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603117     DOI: 10.1164/ajrccm.157.5.9709032

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  631 in total

Review 1.  Home treatment of COPD exacerbations.

Authors:  D S Postma; N H Ten Hacken; H A Kerstjens; G H Koëter
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease.

Authors:  J A Wedzicha
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 3.  Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review.

Authors:  P J Poole; P N Black
Journal:  BMJ       Date:  2001-05-26

Review 4.  Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.

Authors:  Anke Lenferink; Marjolein Brusse-Keizer; Paul Dlpm van der Valk; Peter A Frith; Marlies Zwerink; Evelyn M Monninkhof; Job van der Palen; Tanja W Effing
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

5.  In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model.

Authors:  Yu-Feng Zhou; Meng-Ting Tao; Wei Huo; Xiao-Ping Liao; Jian Sun; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 6.  Management of an acute exacerbation of copd: are we ignoring the evidence?

Authors:  M K Johnson; R D Stevenson
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 7.  Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.

Authors:  Maureen P M H Rutten-van Mölken; Lucas M A Goossens
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

Review 8.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Authors:  K Suresh Babu; Jack A Kastelik; Jaymin B Morjaria
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

9.  Synergistic effects of temperature and humidity on the symptoms of COPD patients.

Authors:  Zhe Mu; Pei-Li Chen; Fu-Hai Geng; Lei Ren; Wen-Chao Gu; Jia-Yun Ma; Li Peng; Qing-Yun Li
Journal:  Int J Biometeorol       Date:  2017-05-31       Impact factor: 3.787

10.  Integrated interdisciplinary care for patients with chronic obstructive pulmonary disease reduces emergency department visits, admissions and costs: a quality assurance study.

Authors:  Esther Dajczman; Chantal Robitaille; Pierre Ernst; Andrew Michael Hirsch; Norman Wolkove; David Small; Judy Bianco; Hartley Stern; Mark Palayew
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.